mood stabilizer

PreclinicalSmall molecule

NNew York State Psychiatric Institute

mood stabilizer is one of 94 small molecule programs targeting Schizophrenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SchizophreniaActive, not recruiting

Bipolar DisorderActive, not recruiting

Mental DisordersCompleted

SchizophreniaPreclinical

Active, not recruiting

Bipolar DisorderPreclinical

Active, not recruiting

Mental DisordersPreclinical

Completed

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Preclinical

1 2

Resotran

Takeda

Preclinical

1 3

Inapsine

Jazz Pharmaceuticals

Preclinical

1 4

Depakote

Ibrance

Lunesta

3 7

Luvox

SSolvay Pharmaceuticals

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Rapamune

PPrism Pharmaceuticals

Preclinical

1 10

Persantine

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia1 trial

Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia

Completed·NNew York State Psychiatric Institute··NCT02775864·81,921 enrolled

Mental Disorders1 trial

Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

Completed·—·N/A·NCT04218981·200 enrolled

Bipolar Disorder1 trial

Bipolar Disorder Research Study for Ages 12 and Older

Completed·KKupfer, David J., M.D.·N/A·NCT00211263·750 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for mood stabilizer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mood stabilizer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mood stabilizer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York State Psychiatric Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNew York State Psychiatric Institute

mood stabilizer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia1 trial

Mental Disorders1 trial

Bipolar Disorder1 trial

References

Drug Info

Quick Facts

Related News